RxDoctor Payments DataLook up a doctor →

Christopher Tolleson, MD

Neurology · Nashville, TNNPI 1225159890

Payments from drug & device makers

$82,026in general payments, 2019–2025

Across 340 payments — averaging $241.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$48K
  • AbbVie$11K
  • Acorda Therapeutics, Inc$6K
  • Neurocrine Biosciences, Inc.$6K
  • Teva Pharmaceuticals USA, Inc.$5K
  • Medtronic$2K
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$1,9387%
  • Speaking & faculty fees$17,74963%
  • Travel & lodging$2,2718%
  • Food & beverage$6,23422%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,026 in reported general payments places this provider in the 80th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$140,059
Medicare patients
494
Services billed
1,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine40$370,465
Austedo XrDeutetrabenazine57$346,601
IngrezzaValbenazine Tosylate30$304,992
RytaryCarbidopa/Levodopa113$202,524
NuplazidPimavanserin Tartrate24$121,187
NeuproRotigotine92$115,971
DuopaCarbidopa/Levodopa16$97,169
GocovriAmantadine Hcl21$92,272
MyrbetriqMirabegron97$57,521
Carbidopa-LevodopaCarbidopa/Levodopa1,033$38,931
LinzessLinaclotide52$30,550
Tetrabenazine43$17,548
Carbidopa-Levodopa ErCarbidopa/Levodopa255$12,543
Rivastigmine51$11,803
Rasagiline Mesylate38$11,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$5,172$717,06697 claims
Neurocrine Biosciences, Inc.Ingrezza$5,730$304,99230 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$292$205,849129 claims
AbbVieDuopa, Linzess$11,017$127,71968 claims
Acadia Pharmaceuticals IncNuplazid$177$121,18724 claims
UCB, Inc.Neupro$189$115,97192 claims
MDD US Operations, LLCGocovri$170$92,27221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 361 neurology providers in Tennessee.

Other neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →